These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 33957387)

  • 21. 6-Heterocyclic carboxylic ester derivatives of gliotoxin lead to LSD1 inhibitors in gastric cancer cells.
    Shan L; Li Z; Chen H; Ge M; Sun Y; Sun Y; Li Y; Li H; Fu L; Liu H
    Bioorg Chem; 2023 Feb; 131():106150. PubMed ID: 36508940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and biological evaluation of coumarin analogs as novel LSD1 inhibitors.
    Sun Y; Lv R; Wu T; Zhang X; Sun Y; Yan J; Zhang Z; Zhao D; Cheng M
    Arch Pharm (Weinheim); 2022 Feb; 355(2):e2100311. PubMed ID: 34862974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
    Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
    Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
    Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
    Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
    Xie R; Li Y; Tang P; Yuan Q
    Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation.
    Duan YC; Guan YY; Zhai XY; Ding LN; Qin WP; Shen DD; Liu XQ; Sun XD; Zheng YC; Liu HM
    Eur J Med Chem; 2017 Jan; 126():246-258. PubMed ID: 27888721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and evaluation of 3-amino/guanidine substituted phenyl oxazoles as a novel class of LSD1 inhibitors with anti-proliferative properties.
    Dulla B; Kirla KT; Rathore V; Deora GS; Kavela S; Maddika S; Chatti K; Reiser O; Iqbal J; Pal M
    Org Biomol Chem; 2013 May; 11(19):3103-7. PubMed ID: 23575971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma.
    Naveen Sadhu M; Sivanandhan D; Gajendran C; Tantry S; Dewang P; Murugan K; Chickamunivenkatappa S; Zainuddin M; Nair S; Vaithilingam K; Rajagopal S
    Bioorg Med Chem Lett; 2021 Feb; 34():127763. PubMed ID: 33359604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of fenoldopam as a novel LSD1 inhibitor to abrogate the proliferation of renal cell carcinoma using drug repurposing strategy.
    Zheng Y; Ma Y; Cao H; Yan L; Gu Y; Ren X; Jiao X; Wan S; Shao F
    Bioorg Chem; 2021 Mar; 108():104561. PubMed ID: 33349457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of orally active chalcones as histone lysine specific demethylase 1 inhibitors for the treatment of leukaemia.
    Li Y; Sun Y; Zhou Y; Li X; Zhang H; Zhang G
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):207-217. PubMed ID: 33307878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.
    Haydn T; Metzger E; Schuele R; Fulda S
    Cell Death Dis; 2017 Jun; 8(6):e2879. PubMed ID: 28617441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors.
    Duan Y; Yu T; Jin L; Zhang S; Shi X; Zhang Y; Zhou N; Xu Y; Lu W; Zhou H; Zhu H; Bai S; Hu K; Guan Y
    Eur J Med Chem; 2023 Jun; 254():115367. PubMed ID: 37086699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of the antitumor activities of a potent DCN1 inhibitor compound 383 targeting LSD1 in gastric cancer.
    Song Z; Gao K; Asmamaw MD; Liu YJ; Zheng YC; Shi XJ; Liu HM
    Eur J Pharmacol; 2022 Feb; 916():174725. PubMed ID: 34953802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors.
    Huang MJ; Guo JW; Fu YD; You YZ; Xu WY; Song TY; Li R; Chen ZT; Huang LH; Liu HM
    Bioorg Med Chem Lett; 2021 Jun; 41():127993. PubMed ID: 33775841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and Biological Evaluation of 1-(2-Aminophenyl)-3-arylurea Derivatives as Potential EphA2 and HDAC Dual Inhibitors.
    Zhu Y; Ran T; Chen X; Niu J; Zhao S; Lu T; Tang W
    Chem Pharm Bull (Tokyo); 2016; 64(8):1136-41. PubMed ID: 27477652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells.
    Vasilatos SN; Katz TA; Oesterreich S; Wan Y; Davidson NE; Huang Y
    Carcinogenesis; 2013 Jun; 34(6):1196-207. PubMed ID: 23354309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells.
    Cao C; Wu H; Vasilatos SN; Chandran U; Qin Y; Wan Y; Oesterreich S; Davidson NE; Huang Y
    Int J Cancer; 2018 Sep; 143(6):1388-1401. PubMed ID: 29633255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
    Cheng C; Yun F; He J; Ullah S; Yuan Q
    Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
    Chen X; Zhao S; Li H; Wang X; Geng A; Cui H; Lu T; Chen Y; Zhu Y
    Eur J Med Chem; 2019 Apr; 168():110-122. PubMed ID: 30802729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and biological evaluation of 2-aminopyrimidine-based LSD1 inhibitors.
    Wang X; Zhang C; Zhang X; Wang J; Zhao L; Zhao D; Cheng M
    Bioorg Chem; 2022 Apr; 121():105699. PubMed ID: 35219044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.